China Biologic Products to Present at Two Upcoming Investor Conferences

PR Newswire
TAI'AN, China
May 12, 2011

TAI'AN, China, May 12, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will present at two investor conferences in New York City in May 2011.

Tristan Kuo, China Biologic's Chief Financial Officer, is scheduled to present at the Eighth Annual Piper Jaffray China Growth Conference on Tuesday, May 17, 2011 at 3:00pm at Le Parker Meridien Hotel.

Mr. Kuo will also present at the Oppenheimer Fifth Annual China Dragon Conference on Wednesday, May 18, 2011, from 11:25am-11:55am at Oppenheimer's office in New York City.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state- owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the appointment of the new directors on the Company's business and operations; the Company's ability to otherwise achieve its commercial objectives; the business strategy, plans, and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.


    For more information, please contact:
    Company Contact:
    Mr. Y. Tristan Kuo
    Chief Financial Officer
    China Biologic Products, Inc.
    Tel: +86-538-6202206
    Email: IR@chinabiologic.com
    www.chinabiologic.com

SOURCE China Biologic Products, Inc.

SOURCE: China Biologic Products, Inc.

China Biologic Products to Present at Two Upcoming Investor Conferences

PR Newswire

TAI'AN, China, May 12, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will present at two investor conferences in New York City in May 2011.

Tristan Kuo, China Biologic's Chief Financial Officer, is scheduled to present at the Eighth Annual Piper Jaffray China Growth Conference on Tuesday, May 17, 2011 at 3:00pm at Le Parker Meridien Hotel.

Mr. Kuo will also present at the Oppenheimer Fifth Annual China Dragon Conference on Wednesday, May 18, 2011, from 11:25am-11:55am at Oppenheimer's office in New York City.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state- owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the appointment of the new directors on the Company's business and operations; the Company's ability to otherwise achieve its commercial objectives; the business strategy, plans, and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Y. Tristan Kuo

Chief Financial Officer

China Biologic Products, Inc.

Tel: +86-538-6202206    

Email: IR@chinabiologic.com

www.chinabiologic.com



SOURCE China Biologic Products, Inc.

Web Site: http://www.chinabiologic.com


print email rss
© 2014 China Biologic Products, Inc. All Rights Reserved.